HUE052571T2 - Lipid alapú gyógyszerészeti készítmények helyi alkalmazáshoz - Google Patents

Lipid alapú gyógyszerészeti készítmények helyi alkalmazáshoz

Info

Publication number
HUE052571T2
HUE052571T2 HUE09816940A HUE09816940A HUE052571T2 HU E052571 T2 HUE052571 T2 HU E052571T2 HU E09816940 A HUE09816940 A HU E09816940A HU E09816940 A HUE09816940 A HU E09816940A HU E052571 T2 HUE052571 T2 HU E052571T2
Authority
HU
Hungary
Prior art keywords
topical application
pharmaceutical preparations
lipid based
based pharmaceutical
lipid
Prior art date
Application number
HUE09816940A
Other languages
English (en)
Hungarian (hu)
Inventor
Shoukath M Ali
Ateeq Ahamd
Moghis U Ahmad
Saifuddin Sheikh
Imran Ahmad
Original Assignee
Jina Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42060413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE052571(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jina Pharmaceuticals Inc filed Critical Jina Pharmaceuticals Inc
Publication of HUE052571T2 publication Critical patent/HUE052571T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
HUE09816940A 2008-09-27 2009-09-25 Lipid alapú gyógyszerészeti készítmények helyi alkalmazáshoz HUE052571T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10071408P 2008-09-27 2008-09-27

Publications (1)

Publication Number Publication Date
HUE052571T2 true HUE052571T2 (hu) 2021-05-28

Family

ID=42060413

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE09816940A HUE052571T2 (hu) 2008-09-27 2009-09-25 Lipid alapú gyógyszerészeti készítmények helyi alkalmazáshoz

Country Status (15)

Country Link
US (1) US9750812B2 (enExample)
EP (1) EP2344198B1 (enExample)
JP (3) JP2012504135A (enExample)
CA (1) CA2737025C (enExample)
CY (1) CY1123579T1 (enExample)
DK (1) DK2344198T3 (enExample)
ES (1) ES2834006T3 (enExample)
HR (1) HRP20201860T1 (enExample)
HU (1) HUE052571T2 (enExample)
LT (1) LT2344198T (enExample)
MX (1) MX2011003207A (enExample)
PL (1) PL2344198T3 (enExample)
PT (1) PT2344198T (enExample)
SI (1) SI2344198T1 (enExample)
WO (1) WO2010036947A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3434264A1 (en) 2008-07-18 2019-01-30 Biomod Concepts Inc. Microparticle for releasing an acitve agent
US8691518B2 (en) 2010-09-24 2014-04-08 Global Life Science Partners Limited Systems and methods for predicting response to minoxidil for the treatment of androgenetic alopecia
US10633688B2 (en) 2010-09-24 2020-04-28 Follea International Systems and methods for predicting response to minoxidil for the treatment of androgenetic alopecia
US9588118B2 (en) 2010-09-24 2017-03-07 Follea International Devices for performing colorimetric assay with plucked human hair
ITMI20102165A1 (it) * 2010-11-23 2012-05-24 Medichem Srl Composizione per il lavaggio dei capelli e del cuoio capelluto
CN106890100A (zh) * 2011-04-25 2017-06-27 朴俊炯 用于预防脱发和促进毛发生长的局部施用的组合物
JP2015514683A (ja) * 2012-02-16 2015-05-21 ブライトサイド イノベーションズ，インコーポレイティド 食品性栄養組成物および使用方法
WO2013160896A1 (en) * 2012-04-25 2013-10-31 Hadasit Medical Research Services And Development Ltd. Pomegranate oil for preventing and treating neurodegenerative diseases
BR102012022034B1 (pt) * 2012-08-31 2020-02-18 Biolab Sanus Farmacêutica Ltda. Nanopartícula polimérica de finasterida, suspensão aquosa contendo a mesma, composição para tratamento de alopecia, processo de preparação de dita composição, e seu uso
BR102012022036B1 (pt) * 2012-08-31 2019-10-01 Biolab Sanus Farmacêutica Ltda. Nanopartícula polimérica de finasterida e minoxidil, processo de sua preparação, suspensão aquosa contendo a mesma, composição farmacêutica, e seu uso
US20150313829A1 (en) * 2012-11-26 2015-11-05 Roberto Queiroga Lautner Topical formulations for the prevention and treatment of alopecia and inhibition of hair growth
WO2014178789A1 (en) * 2013-05-03 2014-11-06 Lipidor Ab Topical composition and carrier for administration of pharmaceutical or cosmetic active ingredients
KR20260039805A (ko) 2013-08-15 2026-03-20 마리 케이 인코포레이티드 주름 치료를 위한 국소 피부 조성물
US20150147382A1 (en) * 2013-09-23 2015-05-28 Exir Nano Sina Company Topical liposomal compositions for delivering hydrophobic drugs and methods preparing same
US11660344B2 (en) 2013-11-17 2023-05-30 Medrx Co., Ltd. Transdermal colloidal solution agent
CN105722502A (zh) * 2013-11-17 2016-06-29 株式会社梅德瑞科思 经皮吸收胶体型液体制剂
NZ732075A (en) 2014-10-29 2022-09-30 Samson Clinical Pty Ltd Detection and treatment of excessive hair shedding
EP3038053B1 (en) 2014-12-22 2019-11-06 Reactive Reality GmbH Method and system for generating garment model data
KR20180016347A (ko) * 2015-04-13 2018-02-14 파운테인 테크놀로지스 인터내셔널, 엘엘씨 초-소형 지질 구조체의 생산을 위한 단일-단계 방법
JPWO2016186157A1 (ja) * 2015-05-19 2018-03-08 株式会社 メドレックス 経皮吸収型液剤
SG11201809154UA (en) * 2016-04-19 2018-11-29 Univ Nanyang Tech Nanoliposomes for sustained delivery of tacrolimus for treatment of anterior segment eye diseases
TWI749091B (zh) 2016-10-28 2021-12-11 法商施維雅藥廠 脂質體調配物
BR112019025104A2 (pt) 2017-05-30 2020-06-23 Glaxosmithkline Biologicals S.A. Método de fabricar um sistema de entrega não viral, sistema de entrega não viral, e, composição
GB2600652B (en) * 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel compositions
KR20240064747A (ko) * 2017-07-12 2024-05-13 삼손 클리니컬 피티와이 엘티디 모발 성장을 촉진시키고, 탈모 또는 과도한 머리카락 빠짐의 치료
WO2019084503A1 (en) * 2017-10-27 2019-05-02 Victor Hasson TOPICAL FORMULATIONS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES COMPRISING HIPPOCRATIC CALVITIS
MX390288B (es) * 2018-02-06 2025-03-20 Centro Int De Cosmiatria S A P I De C V Formulación y método para el tratamiento de la alopecia androgénica.
BR112020024722A2 (pt) 2018-06-04 2021-03-23 Chemistryrx. composições tópicas para estimular crescimento capilar
US11311529B2 (en) 2018-11-08 2022-04-26 Varsona Therapeutics, Inc. Topical formulations of 5-α-reductase inhibitors and uses thereof
EP3886901A1 (en) * 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
WO2021038508A1 (en) 2019-08-30 2021-03-04 Glaxosmithkline Biologicals Sa Jet mixing lipid nanoparticle manufacturing process
US20210353600A1 (en) * 2020-05-12 2021-11-18 Chemistryrx Compositions for treating hair loss
US11311556B2 (en) 2020-05-13 2022-04-26 Varsona Therapeutics, Inc. Topical dutasteride emulsions for treating endocrine therapy-induced alopecia
US11850300B2 (en) 2022-03-17 2023-12-26 Rally Guide Topical lotion composition, methods of use, and methods of preparation
EP4694871A1 (en) * 2023-04-14 2026-02-18 Beijing Jitai Pharmaceutical Technology Co., Ltd. Lipid nanoparticle compositions and uses thereof
WO2025037276A1 (en) * 2023-08-16 2025-02-20 Jina Pharmaceuticals Inc. COMPOSITIONS CONTAINING mTOR INHIBITORS AND LIPIDS
CN118831088B (zh) * 2023-09-06 2025-04-29 北京辰光医药科技有限公司 治疗脱发的药物制剂及其制备方法与用途

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0753661B2 (ja) * 1984-03-08 1995-06-07 フアレス フアーマスーチカル リサーチ エヌブイ プロ―リポソーム組成物及びリポソームの水性分散物を作る方法
US4663167A (en) 1984-04-16 1987-05-05 The Board Of Regents Of The University Of Texas System Composition and method for treatment of disseminated fungal infections in mammals
EP0177223B1 (en) * 1984-09-24 1990-02-28 Michael Mezei Pharmaceutical multi-phase composition
US4897269A (en) * 1984-09-24 1990-01-30 Mezei Associates Limited Administration of drugs with multiphase liposomal delivery system
US4761288A (en) * 1984-09-24 1988-08-02 Mezei Associates Limited Multiphase liposomal drug delivery system
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
US5616334A (en) * 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
US4828837A (en) * 1987-03-30 1989-05-09 Liposome Technology, Inc. Non-crystalline minoxidil composition, its production and application
US5030442A (en) * 1987-03-30 1991-07-09 Liposome Technology, Inc. Non-crystalline minoxidil composition
DE3888994T2 (de) 1987-04-03 1994-11-03 Merck & Co Inc Behandlung von androgener Alopecia mit 17-beta-n-mono-substituierten-carbamoyl-4-aza-5-alpha-androst-1-en-3-onen.
WO1989005636A1 (en) 1987-12-22 1989-06-29 The Liposome Company, Inc. Spontaneous vesiculation of multilamellar liposomes
US5000887A (en) * 1988-05-17 1991-03-19 Liposome Technology, Inc. Preparation of uniform-size liposomes
JP2798302B2 (ja) * 1989-03-31 1998-09-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア リポソームおよび脂質複合体組成物の調製
WO1992003123A1 (en) * 1990-08-28 1992-03-05 Liposome Technology, Inc. Liposome alternative bilayer formulations
US20040175417A1 (en) * 1990-10-19 2004-09-09 Gilead Sciences, Inc. Amphotericin B liposome preparation
GB9111611D0 (en) 1991-05-30 1991-07-24 Sandoz Ltd Liposomes
US6733776B1 (en) * 1992-04-02 2004-05-11 Anticancer, Inc. Method for promoting hair growth
US7556825B2 (en) * 1993-04-02 2009-07-07 Anticancer, Inc. Method for promoting hair growth
US7083572B2 (en) * 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
FI100692B (fi) * 1994-05-24 1998-02-13 Leiras Oy Menetelmä farmaseuttisten koostumusten valmistamiseksi, jolloin koostu mukset pohjautuvat mikroemulsiogeeleihin sekä uusia mikroemulsioihin p ohjautuvia geelejä
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
US6001812A (en) * 1995-04-28 1999-12-14 Societe L'oreal S.A. Modulating body/cranial hair growth with derivatives of the α-type melanocyte-stimulating hormone
JPH0971513A (ja) * 1995-09-07 1997-03-18 Taisho Pharmaceut Co Ltd 育毛剤
US5834014A (en) * 1995-10-06 1998-11-10 The Regents Of The University Of Michigan Stimulation of hair follicles
JP3596835B2 (ja) * 1996-08-13 2004-12-02 株式会社ノエビア 養毛剤
US6030948A (en) * 1997-12-19 2000-02-29 Mann; Morris A. Hair regeneration compositions for treatment of alopecia and methods of application related thereto
US6265412B1 (en) 1998-05-26 2001-07-24 Taisho Pharmaceutical Co., Ltd. Minoxidil compositions for external use
US6284234B1 (en) 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
JP4444385B2 (ja) * 1999-02-25 2010-03-31 帝人株式会社 リポソーム用時調製用キット
IL144828A0 (en) * 1999-03-11 2002-06-30 Fujisawa Pharmaceutical Co A pipecolic acid derivative containing liposome composition
CA2309373A1 (en) * 1999-05-27 2000-11-27 Johnson & Johnson Consumer Companies, Inc. Novel topical formulations
US6596266B2 (en) * 2000-02-18 2003-07-22 Natural Science, Inc. Compositions containing minoxidil and saw palmetto for treating baldness
JP4780429B2 (ja) * 2000-04-07 2011-09-28 大正製薬株式会社 ミノキシジル含有製剤
CA2408152A1 (en) * 2000-05-05 2001-11-15 Wisconsin Alumni Research Foundation Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
IN188843B (enExample) * 2000-06-22 2002-11-09 Vinod Daftary Gautam Dr
WO2002007728A1 (en) 2000-07-19 2002-01-31 Knowles W Roy Hair loss prevention
DE10036799A1 (de) * 2000-07-28 2002-02-07 Beiersdorf Ag Neues Mittel zur Behandlung der Haare und der Kopfhaut
SE0100374D0 (sv) * 2001-02-07 2001-02-07 Pharmacia Ab Novel compositions of potassium channel openers and protein kinase c inhibitors and use thereof
AU2002312777B2 (en) * 2001-03-27 2007-07-05 Phares Pharmaceutical Research N.V. Method and composition for solubilising a biologically active compound with low water solubility
JP4796260B2 (ja) * 2001-04-05 2011-10-19 大正製薬株式会社 ミノキシジル含有製剤
WO2003013245A1 (en) * 2001-08-07 2003-02-20 Wisconsin Alumni Research Foundation Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy
US6656460B2 (en) 2001-11-01 2003-12-02 Yissum Research Development Method and composition for dry eye treatment
CA2495913A1 (en) * 2002-08-23 2004-03-04 Medigene Oncology Gmbh Non-vesicular cationic lipid formulations
EP1551423B1 (en) * 2002-10-03 2008-04-09 University of Mississippi Compositions comprising amphotericin B comprising less than 4 % impurities
EA200500659A1 (ru) * 2002-10-16 2005-10-27 Неофарм, Инк. Способ получения кардиолипина или его аналога (варианты) и содержащей их липосомы, способы использования кардиолипина или его аналогов в лечении болезней (варианты) и содержащая их композиция (варианты) и ее применение
JP2004155690A (ja) * 2002-11-05 2004-06-03 Shiseido Co Ltd 養毛剤組成物
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
EP1643971A2 (en) 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
KR100508019B1 (ko) * 2003-07-19 2005-08-17 한미약품 주식회사 고순도 1-안드로스텐 유도체의 제조 방법
ITMI20032019A1 (it) * 2003-10-17 2005-04-18 Fidia Farmaceutici Microemulsioni di retinoidi e composizioni farmaceutiche che le contengono
AU2005245018A1 (en) * 2004-05-21 2005-12-01 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
WO2006026730A2 (en) * 2004-08-30 2006-03-09 Iken Tissue Therapeutics, Inc. Cultured three dimensional tissues and uses thereof
CA2582374A1 (en) 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
JP2008534607A (ja) * 2005-03-30 2008-08-28 ワイス Ｂｍｐを投与することによって毛髪の成長を刺激するための方法
JP2006290841A (ja) * 2005-04-14 2006-10-26 Nippon Zettoc Co Ltd 化粧料の製造方法および化粧料
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
EP2029106A2 (en) 2006-06-07 2009-03-04 Foamix Ltd. Foamable vehicle comprising polypropylene glycol alkyl ether and pharmaceutical compositions thereof
HUE031951T2 (en) * 2006-10-10 2017-08-28 Jina Pharmaceuticals Inc Aqueous systems for lipid-based drug compounds; preparations, processes and their use
GB0623838D0 (en) * 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
CN101559038B (zh) * 2009-05-21 2011-03-16 江苏黄河药业股份有限公司 非那雄胺的固体脂质纳米粒及其制备方法

Also Published As

Publication number Publication date
LT2344198T (lt) 2021-02-25
PL2344198T3 (pl) 2021-05-31
JP2014221784A (ja) 2014-11-27
US20110212167A1 (en) 2011-09-01
US9750812B2 (en) 2017-09-05
JP2012504135A (ja) 2012-02-16
PT2344198T (pt) 2020-12-04
JP2017048188A (ja) 2017-03-09
EP2344198A4 (en) 2013-01-09
WO2010036947A3 (en) 2010-06-10
JP6196943B2 (ja) 2017-09-13
ES2834006T3 (es) 2021-06-16
HRP20201860T1 (hr) 2021-04-16
EP2344198B1 (en) 2020-11-04
DK2344198T3 (da) 2020-11-30
CA2737025A1 (en) 2010-04-01
SI2344198T1 (sl) 2021-01-29
EP2344198A2 (en) 2011-07-20
MX2011003207A (es) 2011-11-04
CY1123579T1 (el) 2022-03-24
WO2010036947A2 (en) 2010-04-01
CA2737025C (en) 2012-09-04

Similar Documents

Publication Publication Date Title
SI2344198T1 (sl) Farmacevtski pripravki na lipidni osnovi za topično uporabo
TWI367110B (en) Topical pharmaceutical formulation
GB2450753B (en) New Pharmaceutical formulation
IL204589A0 (en) Cosmetic or pharmaceutical composition for topical application
SG10201703707YA (en) Pharmaceutical formulation containing improved antibody molecules
ZA201400071B (en) Topical formulations having enhanced bioavailability
IL216171A (en) Lipidic Compound, Method for Preparing the Compound, Pharmaceutical and Lipid Preparations Containing Their Composition and Uses
ZA201103333B (en) Pharmaceutical formulation 514
ZA201104348B (en) Pharmaceutical preparation
PL2344130T3 (pl) Kompozycje farmaceutyczne do miejscowego stosowania
IL214402A0 (en) Transdermal pharmaceutical preparations
PL394605A1 (pl) Trwała złożona kompozycja farmaceutyczna
GB0815972D0 (en) Pharmaceutical preparation
IL208788A (en) Pharmacy-based formulation
EP2124938A4 (en) TOPICAL FORMULATION
EP2310022A4 (en) TOPIC MEDICINE
GB0612556D0 (en) Topical pharmaceutical formulations
GB2465746B (en) Pharmaceutical composition for topical application
GB0603151D0 (en) Topical pharmaceutical formulation
HK1163507A (en) Transdermal pharmaceutical preparations
AU2008903115A0 (en) Pharmaceutical Formulation
HK1149191A (en) Pharmaceutical dosage form
GB0805292D0 (en) Pharmaceutical formulation
GB0810217D0 (en) Pharmaceutical formulations
GB0813031D0 (en) Pharmaceutical formulations